Screener / SEC EDGAR /CIK 0001321732 /10-K filed Feb 25, 2026, compared with Feb 18, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Instruments

Penumbra Inc PEN

Compare with peers Embed
The 10-K against last year's

98 changes: 23 added, 10 removed, 64 reworded, 1 quiet changes

10-K Feb 25, 2026 vs Feb 18, 2025

10-K 0001321732-26-000007 (Feb 25, 2026) vs 10-K 0001321732-25-000012 (Feb 18, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

271 paragraphs · 21 new · 54 reworded · 6 gone · 10-K Feb 25, 2026 against Feb 18, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 256 · 48% changed Every version of it
Our inability to maintain severe adverse events. A natural disaster or grow the market acceptance other catastrophic event in any of our existing products, or to develop and market new products, major markets could result in write-offs of our inventory and otherwise have a material and adverse effect impact on our business, financial condition, results of operations, financial condition or cash flows.
Paragraph 225 · 46% changed Every version of it
Short selling is the practice of selling securities that the seller does not own but rather has borrowed from a third-party with the intention of buying identical securities back at a later date to return to the lender. The short seller hopes to profit from a decline in the value of the securities between the sale of the borrowed securities and the purchase of the replacement shares, as the short seller expects to pay less in that purchase than it received in the sale. As it is in the short seller’s best interests for the price of the stock to decline, many short sellers publish, or arrange for the publication of, negative opinions regarding the relevant issuer and its business prospects in order to create negative market momentum and generate profits for themselves after selling a stock short. These short attacks have led to selling of shares in the market. We have been in the past, and may be in the future, subject to such attacks by short sellers. If we are the subject of unfavorable allegations, we may have to expend a significant amount of resources to investigate such allegations and/or defend ourselves. While we would strongly defend against any such short seller attacks, we may be constrained in the manner in which we can proceed against the relevant short seller by applicable state law or issues of commercial confidentiality. Such a situation could be costly and time-consuming, and could be distracting for our management team.
Paragraph 116 · 43% changed Every version of it
FDA and other foreign regulatory authorities worldwide also conduct periodic inspections of our facilities to determine compliance with FDA’s QSR requirements, EU MDR requirements and all comparable foreign regulations. Product approvals or clearances by FDA can be withdrawn, and new product approvals or clearances by FDA and foreign regulatory bodies can be delayed, due to failure to comply with regulatory requirements or the occurrence of unforeseen problems following initial approval or clearance of a product. In addition, state or federal legislation or regulations may impact key manufacturing processes, such as sterilization, which could require expensive and time-consuming changes to our manufacturing processes as well as the need for additional regulatory clearances or approvals. Failure to comply with regulatory requirements or the discovery of previously unknown problems with a product or manufacturer could result in fines, delays or suspensions of regulatory approvals or clearances, seizures or recalls of products (with the attendant expenses and adverse competitive impact), the banning of a particular device, an order to replace or refund the cost of any device previously manufactured or distributed, operating restrictions and criminal prosecution, as well as decreased sales as a result of negative publicity and product liability claims, all of which could have a material adverse effect on our business, results of operation, financial condition or cash flows.
Paragraph 154 · 40% changed Every version of it
Competitors may infringe our issued patents or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent’s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly, which could adversely affect our competitive business position, business prospects and financial condition.
Paragraph 191 · 34% changed Every version of it
In addition to patent protection, we also rely on confidential proprietary information, including trade secrets and know-how, to develop and maintain our competitive position. We seek to protect our confidential proprietary information, in part, by entering into confidentiality agreements with our employees, consultants, collaborators, strategic partners and others upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual’s relationship with us be kept confidential. Our agreements with employees and our personnel policies also provide that any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. However, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms. Thus, despite such agreements, such inventions may become assigned to third parties. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our employees, consultants or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions. To the extent that an individual who is not obligated to assign rights in intellectual property to us is rightfully an inventor of intellectual property, we may need to obtain an assignment or a license to that intellectual property from that individual, or a third party or from that individual’s assignee. Such assignment or license may not be available on commercially reasonable terms or at all.
Paragraph 169 · 33% changed Every version of it
•incur substantial monetary liability for infringement or other violations of intellectual property rights, which we may have to pay if a court decides that the product or technology at issue infringes or violates the third party’s rights, and if the court finds that the infringement was willful, we could be ordered to pay treble damages and the third party’s attorneys’ fees;
Paragraph 123 · 33% changed Every version of it
We are required to register with FDA as a device manufacturer and as a result, we are subject to periodic inspection by FDA for compliance with FDA’s QSR QMSR requirements, which requires manufacturers of medical devices to adhere to certain requirements, including testing, quality control and documentation procedures. In addition, the U.S. federal Medical Device Reporting regulations require us to provide information to FDA whenever there is evidence that reasonably suggests that a device may have caused or contributed to a death or serious injury, or has malfunctioned, and if the malfunction were to recur, it would be likely to cause or contribute to a death or serious injury. Compliance with applicable regulatory requirements is subject to continual review and is rigorously monitored through periodic inspections by FDA. In the European Community, we are required to maintain certain ISO certifications in order to sell products and we undergo periodic inspections by notified bodies to obtain and maintain these certifications. We received certification to ISO 13485:2016 in 2018 and successfully completed our most recent recertification audit in 2024. Compliance with this standard is subject to continual review and is monitored through periodic inspections by our notified body. Some foreign countries, most notably Japan and Brazil, have similar requirements or may require inspections of our manufacturing facilities before approving a product for sale in their country. We participate in the Medical Device Single Audit Program (“MDSAP”) which allows for certification and review of compliance to standards and regulations required in the United States, Canada, Brazil, Australia, and Japan. We received our first MDSAP certification in 2018 and successfully completed our most recent recertification audit in 2024. Some of our suppliers are subject to the same or similar scrutiny. If we or our suppliers fail to adhere to QSR, ISO or other regulatory requirements, this could delay production of our products and lead to fines, difficulties in obtaining regulatory clearances or approvals, recalls or other consequences, which could in turn have a material adverse effect on our business, results of operation, financial condition or cash flows.
Paragraph 50 · 31% changed Every version of it
In addition, the research, development, marketing and sales of our products are dependent, in part, upon our working relationships with specialist physicians and other healthcare providers. We rely on them to provide us with knowledge and feedback regarding our products and the marketing of our products. If we are unable to develop or maintain strong relationships with specialist physicians and other healthcare providers and receive their advice and input, the development and marketing of our products could suffer, which could materially adversely affect our business, results of operations, financial condition or cash flows.

MD&A

85 paragraphs · 2 new · 35 reworded · 4 gone · 10-K Feb 25, 2026 against Feb 18, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 11 · 49% changed
Refer transaction consideration is paid approximately 73% in cash and approximately 27% in shares of Boston Scientific’s common stock. The Merger is expected to Notes “6. Asset Acquisition” close by the end of 2026, subject to customary closing conditions, including approval by our stockholders and “7. Intangible Assets” regulatory approvals. See Note “20. Subsequent Events” to our consolidated financial statements in Part II, Item 8 of this Form 10-K for more information.
Paragraph 32 · 45% changed
We follow FASB ASC 740-10 “Accounting for Uncertainty in Income Taxes” that prescribes a financial statement recognition threshold and measurement attribute for uncertain tax positions taken or expected to be taken on our income tax returns, and also provides guidance on derecognition, classification, interest and penalty accrual, accounting in interim periods, and disclosure requirements. We include interest and penalties related to unrecognized tax benefits within income tax expense in the accompanying consolidated statements of operations.
Paragraph 56 · 40% changed
SG&A expenses increased by $67.5 $89.4 million, or 13.3%, 15.6%, to $663.4 million in 2025, from $574.0 million in 2024, from $506.5 million in 2023. 2024. The increase was primarily due to a $34.3 $74.5 million increase in personnel-related expenses driven by an increase in headcount and related expenses to support our growth, a $10.0 $10.4 million increase in costs related to marketing events, and a $9.8 $7.7 million increase in other professional services. travel-related expenses. This was partially offset by a $4.8 million decrease in non-recurring litigation related expenses, including settlement costs and legal fees, associated with wage and hour complaints filed against the Company in 2023 and a $4.7 million decrease in amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition due to the impairment of long-lived assets associated with the immersive healthcare business in the second quarter of 2024.
Paragraph 62 · 33% changed
Our provision for income taxes was $27.4 million in 2025, which was primarily due to income taxes imposed on our worldwide profits, partially offset by excess tax benefits from stock-based compensation attributable to our U.S. jurisdiction. Our provision for income taxes was $6.9 million in 2024, which was primarily due to income taxes imposed on our worldwide profits. Our benefit from income taxes was $11.3 million in 2023, which was primarily due to income taxes imposed on our worldwide profits, offset by excess tax benefits from stock-based compensation attributable to our U.S. jurisdiction and tax benefits from releasing the valuation allowance against federal research and development credit DTAs net of ASC 740-10 reserve and recording a partial release of our California DTAs. Our effective tax rate was 13.4% in 2025, compared to 32.9% in 2024, compared to (14.2)% in 2023. 2024. Our change in effective tax rate was primarily attributable to an increase in excess tax benefits from stock-based compensation and substantial tax benefits recorded from releasing the valuation allowance against federal research and development credits and partial California DTAs in 2023. compensation.
Paragraph 53 · 32% changed
R&D expenses increased decreased by $10.4 $5.0 million or 12.3%, 5.3%, to $89.8 million in 2025, from $94.8 million in 2024, from $84.4 million in 2023. 2024. The increase decrease was primarily due to a $3.3 $14.2 million increase decrease in product development and testing expenses associated with our immersive healthcare business. Excluding these costs, $2.6 R&D expenses increased by $9.2 million in one-time expenses in connection with the wind down of the Immersive Healthcare business, and a $1.8 million increase in personnel-related expenses driven by an increase in headcount and related expenses 2025 to support our continued growth.
Paragraph 77 · 29% changed
Net cash provided by used in investing activities was $54.8 $404.6 million in 2022 2025 and primarily consisted of purchases of marketable investments, net of proceeds from maturities and sales of marketable investments investments, of $74.1 million, partially offset by $340.9 million and capital expenditures of $19.3 million. $63.7 million primarily driven by investments related to the construction of our Costa Rica manufacturing facility.
Paragraph 60 · 28% changed
During the year ended December 31, 2024, we made the strategic decision to wind down and exit our Immersive Healthcare business, and as a result we incurred $115.3 million in impairment and other charges in connection with this decision. The Company incurred a $33.4 million charge to cost of revenue for the write-down of Immersive Healthcare inventory to net realizable value, an impairment charge to long-lived assets consisting of $58.9 million in finite-lived intangible assets and $18.0 million in property and equipment, and severance and other associated costs of $5.0 million included in research and development and sales, general and administrative within the consolidated statement of operations. Refer to Note “4. Exit of Immersive Healthcare Business” to our consolidated financial statements in Part II, Item 8 of this Form 10-K for more information.
Paragraph 50 · 26% changed
Gross margin was increased by 3.9 percentage points to 67.1% in 2025. This compares to gross margin of 63.2% in 2024, including a $7.3 million reduction in revenue resulting from the Italian government’s payback provision, which requires medical device companies to make payments to the Italian government for any deficit created by Italian budget overspend on medical devices, and included a one-time $33.4 million inventory charge to cost of revenue in connection with the impairment of our Immersive Healthcare immersive healthcare asset group (refer to Note “4. Exit of Immersive Healthcare Business” to our consolidated financial statements in Part II, Item 8 of this Form 10-K for more information). This compares to gross margin of 64.5% in 2023. The impact of the $7.3 million Italian payback provision and one-time $33.4 million inventory charge decreased our gross margin by 3.0 2.8 percentage points in 2024. Gross margin is impacted by product mix, regional mix, and production initiatives to support demand and create future efficiencies. As such, with favorable product mix, improvement

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors212 words changed in this paragraph; it is 55% similar to last year's version.
We are required to register with FDA as a device manufacturer and as a result, we are subject to periodic inspection by FDA for compliance with FDA’s QSR QMSR requirements, which requires manufacturers of medical devices to adhere to certain requirements, including testing, quality control and documentation procedures. In addition, the U.S. federal Medical Device Reporting regulations require us to provide information to FDA whenever there is evidence that reasonably suggests that a device may have caused or contributed to a death or serious injury, or has malfunctioned, and if the malfunction were to recur, it would be likely to cause or contribute to a death or serious injury. Compliance with applicable regulatory requirements is subject to continual review and is rigorously monitored through periodic inspections by FDA. In the European Community, we are required to maintain certain ISO certifications in order to sell products and we undergo periodic inspections by notified bodies to obtain and maintain these certifications. We received certification to ISO 13485:2016 in 2018 and successfully completed our most recent recertification audit in 2024. Compliance with this standard is subject to continual review and is monitored through periodic inspections by our notified body. Some foreign countries, most notably Japan and Brazil, have similar requirements or may require inspections of our manufacturing facilities before approving a product for sale in their country. We participate in the Medical Device Single Audit Program (“MDSAP”) which allows for certification and review of compliance to standards and regulations required in the United States, Canada, Brazil, Australia, and Japan. We received our first MDSAP certification in 2018 and successfully completed our most recent recertification audit in 2024. Some of our suppliers are subject to the same or similar scrutiny. If we or our suppliers fail to adhere to QSR, ISO or other regulatory requirements, this could delay production of our products and lead to fines, difficulties in obtaining regulatory clearances or approvals, recalls or other consequences, which could in turn have a material adverse effect on our business, results of operation, financial condition or cash flows.

Source: Item 1A, 10-K 0001321732-26-000007 vs Item 1A, 10-K 0001321732-25-000012

MD&A131 words changed in this paragraph; it is 33% similar to last year's version.
The three months ended September 30, 2024, the Company is also subject to certain royalty obligations repurchased an aggregate of 517,763 shares under a license agreement with amounts due thereunder fluctuating depending on sales levels. Royalty expense included in the ASR at an aggregate cost of sales $100.4 million, including legal and financial advisor fees of $0.4 million associated with the repurchase. During the three months ended September 30, 2025 and December 31, 2025, the Company’s Board of Directors extended the repurchase authorization for the years ended remaining $100.0 million to December 31, 2024, 2023 2025 and 2022 was $2.6 million, $2.6 December 31, 2026, respectively. As of December 31, 2025, the Company had remaining authority to purchase $100.0 million and $2.5 million, respectively. For more information on these royalty obligations, refer of its common stock under the share repurchase authorization. Refer to Note “10. Commitments and Contingencies” “12. Share Repurchase Program” to our consolidated financial statements in Part II, Item 8 of this Form 10-K. 10-K for more information.

Source: Item 7, 10-K 0001321732-26-000007 vs Item 7, 10-K 0001321732-25-000012

Legal Proceedings89 words changed in this paragraph; it is 83% similar to last year's version.
On April 7, 2023, a former contractor who had been retained by the Company through a third party staffing agency filed a putative class action lawsuit as well as a Private Attorney General Act (“PAGA”) representative action complaint against the Company in the Superior Court of the State of California for the County of Alameda, on behalf of the contractor and similarly situated Company contractors and employees in California, alleging various claims pursuant to the California Labor Code related to wages, overtime, meal and rest breaks, reimbursement of business expenses, wage statements and records, and other similar allegations. Additionally, on April 10, 2023, a current employee of the Company filed a PAGA representative action complaint against the Company in the Superior Court of the State of California for the County of Alameda, on behalf of the employee and similarly situated Company employees in California, alleging similar claims. The complaints seek sought payment of various alleged unpaid wages, penalties, interest and attorneys’ fees in unspecified amounts. Following mediation in April 2024, in May 2024 the parties entered into a formal agreement to settle the claims for an aggregate amount of $4.6 million, subject to approval by the court. The proposed settlement agreement court, which was initially submitted to the court for preliminary approval on June 18, 2024, and the court granted preliminary approval of the settlement agreement on October 14, 2024. Class notices have been mailed, and the final settlement approval hearing is scheduled for in March 11, 2025. The Company recorded an accrual of $4.6 million in its financial statements for the three months ended March 31, 2024 related to these matters. The Company completed substantially all payments under the settlement agreement during the three months ended June 30, 2025. In February 2026, following payment of the remaining amounts under the settlement agreement, the court granted final approval of the settlement.

Source: Item 3, via Note 10 – Commitments and Contingencies, 10-K 0001321732-26-000007 vs Item 3, via Note 10 – Commitments and Contingencies, 10-K 0001321732-25-000012

Accounting Policies79 words changed in this paragraph; it is 66% similar to last year's version.
The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When such an event occurs, management determines whether there has been impairment by comparing the anticipated undiscounted future net cash flows to the related asset group’s carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset. The Company reviewed long-lived assets for impairment and determined there were no indicators of impairment during the years ended December 31, 2025 or 2023. As a result, no impairment charge was recognized. During the year ended December 31, 2024, the Company recorded an impairment charge of $76.9 million related to the Company’s immersive healthcare asset group. Refer to Note “4. Exit of Immersive Healthcare Business” for more details.

Source: Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001321732-26-000007 vs Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001321732-25-000012

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of PEN's Risk Factors and MD&A, 10-K Feb 25, 2026 against 10-K Feb 18, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
On January 14, 2026, we entered into the Merger Agreement with Boston Scientific Corporation and Merger Sub, pursuant to which Boston Scientific Corporation has agreed to acquire us for $374 per share pursuant to the Merger, with our stockholders having the right to elect, for each share of our common stock held by them, to receive $374 in cash or 3.8721 shares of Boston Scientific Corporation’s common stock (valued at $374 based on the volume weighted average price of Boston Scientific Corporation’s common stock over the 10 trading days ending January 13, 2026), subject to proration, so that the total transaction consideration is paid approximately 73% in cash and approximately 27% in shares of Boston Scientific Corporation’s common stock. Uncertainty about the effect of the Merger Agreement and the Merger on our customers, employees, suppliers, vendors, and business partners may have an adverse effect on our business and operations that may be material to our company. For example, our employees may experience uncertainty about their roles following the Merger. There can be no assurance we will be able to attract and retain key talent, including senior leaders, engineers, salespeople, and others to the same extent that we have previously been able to attract and retain employees. Any loss or distraction of such employees could have a material adverse effect on our business and operations. In addition, we have diverted, and will continue to divert, significant management attention and resources towards the completion of the Merger, which could materially adversely affect our business and results of operations.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedRisk Factors
Moreover, our customers may experience uncertainty associated with the Merger, including with respect to possible changes to our products, technology or policies. Similarly, our suppliers, vendors, business partners and distribution channels may experience uncertainty associated with the Merger, including with respect to current or future business relationships with us. Uncertainty may cause customers to refrain from purchasing our products and to instead purchase our competitors’ products, and suppliers, vendors and business partners may seek to change existing business relationships, which could result in an adverse effect on our business, results of operations and financial condition in a way that may be material to our company.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedRisk Factors
Pursuant to the terms of the Merger Agreement, until the Merger becomes effective or the Merger Agreement is terminated, we are subject to certain restrictions on the conduct of our business, including in certain cases restrictions on our ability to enter into certain material contracts, acquire or dispose of assets outside of the ordinary course of business, incur indebtedness or make unbudgeted capital expenditures. These restrictions may prevent us from taking actions with respect to our business that we may consider advantageous, and result in our inability to respond effectively to competitive pressures and industry developments and may otherwise harm our business and results of operations.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedRisk Factors
Completion of the Merger is subject to conditions beyond our control that may prevent, delay or otherwise adversely affect its completion in a material way, including the approval of our stockholders and the expiration or termination of applicable waiting periods and the receipt of certain clearances under antitrust and competition laws. If the Merger or a similar transaction is not completed, the share price of our common stock may decline to the extent that the current market price of our common stock reflects an assumption that a transaction will be completed. In addition, under circumstances defined in the Merger Agreement, we may be required to pay Boston Scientific Corporation a termination fee of $525.0 million in the event the Merger is not completed. Further, a failure to complete the Merger may result in negative publicity for us in the investment community. Any disruption to our business resulting from the announcement and pendency of the Merger, including any adverse changes in our relationships with our customers, suppliers, vendors and business partners could continue or accelerate in the event of a failure to complete the Merger. There can be no assurance that our business, these relationships or our financial condition will not be adversely affected if the Merger is not consummated.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedRisk Factors
We have incurred significant legal, advisory and financial services fees in connection with Merger. We have incurred, and expect to continue to incur, additional costs in connection with the satisfaction of the various conditions to closing of the
Read it in 10-K Feb 25, 2026 at sec.gov
AddedRisk Factors
Merger, including seeking approval from our stockholders and from applicable regulatory authorities. If there is any delay in the consummation of the Merger, these costs could increase significantly.
Read it in 10-K Feb 25, 2026 at sec.gov
Show the other 41
AddedRisk Factors
Litigation is very common in connection with the sale of public companies, regardless of whether the claims have any merit. One of the conditions to consummating the Merger is that no order enjoining, prohibiting or otherwise making illegal the consummation of the Merger shall have been issued by any governmental authority, including a court. Consequently, if any lawsuit challenging the Merger is successful in obtaining an order preventing the consummation of the Merger, that order may delay or prevent the Merger from being completed. While we will evaluate and defend against any lawsuits, the time and costs of defending against litigation relating to the Merger may adversely affect our business.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedRisk Factors
Provisions of the Merger Agreement may deter alternative business combinations and could negatively impact our stock price if the Merger Agreement is terminated in certain circumstances.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedRisk Factors
The Merger Agreement prohibits us from soliciting, initiating, knowingly facilitating or knowingly encouraging any inquiries, proposals or offers that would be reasonably expected to lead to certain alternative takeover proposals with any third party, and from taking other similar actions, subject to exceptions set forth in the Merger Agreement. The Merger Agreement also provides for the payment by us of a termination fee of $525.0 million if the Merger Agreement is terminated in certain circumstances in connection with a competing third-party acquisition proposal. These provisions limit our ability to pursue offers from third parties that could result in greater value to our stockholders. The obligation to pay the termination fee may also discourage a third party from pursuing an alternative acquisition proposal. If the Merger Agreement is terminated and we determine to seek another business combination, we cannot assure our stockholders that we will be able to negotiate a transaction with another company on terms comparable to the terms of the Merger Agreement, or that we will avoid incurrence of any fees associated with the termination of the Merger Agreement. In the event the Merger Agreement is terminated, our stock price may decline.
Read it in 10-K Feb 25, 2026 at sec.gov
RemovedRisk Factors
long term international revenue growth. We have in the past experienced turnover with some of our distributors that has adversely affected sales in the countries in which those distributors operate. Similar occurrences could happen in the future.
Read it in 10-K Feb 18, 2025 at sec.gov
RemovedRisk Factors
your investment in our common stock since you might be unable to sell your shares at or above the price you paid for such shares. Factors that could cause fluctuations in the market price of our common stock include the following:
Read it in 10-K Feb 18, 2025 at sec.gov
RemovedRisk Factors
partners. To the extent that such disruptions occur, our customers and partners may lose confidence in our company and we may lose business or brand reputation, resulting in a material and adverse effect on our business, financial condition, results of operations or cash flows.
Read it in 10-K Feb 18, 2025 at sec.gov
RewordedRisk Factors
Failure to comply with regulatory requirements or the discovery of previously unknown problems with a product or manufacturer could result in fines, delays or suspensions of regulatory approvals or clearances, seizures or recalls of products (with the attendant expenses and adverse competitive impact), the banning of a particular device, an order to replace or refund the cost of any device previously manufactured or distributed, operating restrictions and criminal prosecution, as well as decreased sales as a result of negative publicity and product liability claims, all of which could have a material adverse effect on our business, results of operation, financial condition or cash flows.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
If the information we rely upon to run our businesses were to be found to be inaccurate or unreliable, if we fail to maintain or protect our information technology systems and data integrity effectively, if we fail to develop and implement new or upgraded systems to meet our business needs in a timely manner, or if we fail to anticipate, plan for or manage significant disruptions to these systems, our competitive position could be harmed, we could have operational disruptions, we could lose existing customers, have difficulty preventing, detecting, and controlling fraud, have disputes with customers, specialist physicians and other healthcare providers, have regulatory sanctions or penalties imposed or other legal problems, incur increased operating and administrative expenses, lose revenues as a result of a data privacy breach or theft of intellectual property or suffer other adverse consequences, any of which could have a material adverse effect on our business, results of operations, financial condition or cash flows.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
If they succeed in registering or developing common law rights in such trademarks, and if we are not successful in challenging such third-party rights, we may not be able to use these trademarks to market our products in those countries where such third parties have registered such trademarks or obtained such common law rights.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
For example, certain unique macroeconomic and geopolitical factors, including those as a result armed conflict in various parts of the Russian invasion of Ukraine or conditions in the Middle East as a result of the Israel-Hamas conflict, world, may cause instability and volatility in the global financial markets and disruptions within the healthcare industry that may negatively impact our business.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
Accordingly, although we have multiple contracts with many major GPOs and IDNs, the members of such groups may choose to purchase from our competitors due to the price or quality offered by such competitors, which could result in a decline in our sales and profitability.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
These broad market and industry factors may harm the market price of our common stock, regardless of our operating performance, and could cause you to lose all or part of your investment in our common stock since you might be unable to sell your shares at or above the price you paid for such shares.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
We are expanding and renovating our existing facilities around the world but particularly world, including in Alameda, Alameda and Roseville California, and establishing new manufacturing facilities in Costa Rica, driven by our need to expand the space available for our product manufacturing and product development and test testing capacities, as well as our need for additional information technology and office space.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
If key personnel were to leave Penumbra, either to join our competitors or otherwise, we may not be able to attract and retain equally qualified personnel to replace them, which could harm our ability to develop and successfully grow our business.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
We currently produce substantially all of our products at our manufacturing facilities in Alameda and Roseville, California, and, while we have entered into agreements to acquire property in Costa Rica and construct a manufacturing facility and warehouse for our products, we can give no assurance that these facilities will be adequate for our future needs.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
In addition, an injury or death that is caused by the activities of our suppliers, such as those that provide us with components and raw materials, or by an aspect of a treatment used in combination with our products, such as a complementary drug or anesthesia, may be the basis for a claim against us by patients, hospitals, healthcare providers or others purchasing or using our products, even if our products were not the actual cause of such injury or death.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
In order to maintain and improve the effectiveness of our disclosure controls and procedures and internal control over financial reporting, we have expended, and anticipate that we will continue to expend, significant resources, including accounting-related costs and significant management oversight.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedMD&A
On January 14, 2026, we entered into the Merger Agreement with Boston Scientific Corporation and Merger Sub, pursuant to which Boston Scientific Corporation has agreed to acquire us in the Merger at an enterprise value of approximately $14.5 billion. Under the terms of the Merger Agreement, which has been approved by the board of directors of each of the Company and Boston Scientific Corporation, the transaction values each share of our common stock at $374 per share, with our stockholders having the right to elect, for each share of our common stock held by them, to receive $374 in cash or 3.8721 shares of Boston Scientific Corporation’s common stock (valued at $374 based on the volume weighted average price of Boston Scientific Corporation’s common stock over the 10 trading days ending January 13, 2026), subject to proration, so that the total
Read it in 10-K Feb 25, 2026 at sec.gov
AddedMD&A
On July 4, 2025, President Trump signed the One Big Beautiful Bill Act (“OBBBA”) into law, which extends and modifies various domestic and international business tax framework originally enacted under the Tax Cuts and Jobs Act (“TCJA”). The legislation includes multiple effective dates, with certain provisions taking effect in 2025 and others through 2027. We evaluated the OBBBA and included its impact within our consolidated financial statements. We will continue to evaluate the full impact of these legislative changes as additional supplemental guidance becomes available.
Read it in 10-K Feb 25, 2026 at sec.gov
RemovedMD&A
The fair value of in-process research and development asset (“IPR&D”) projects acquired in a business combination are capitalized and accounted for as indefinite-lived intangible assets until the underlying project is completed, at which point the intangible asset will be accounted for as a finite-lived intangible asset. If a project is abandoned prior to completion, the carrying value of the IPR&D asset is written off. IPR&D acquired in an asset acquisition for use in research and development activities with no alternative future use are expensed in the consolidated statements of operations on the acquisition date. Accounting for acquisitions of IPR&D requires the Company to make certain judgements to determine if the transaction should be accounted for as an asset acquisition or a business combination, as well as assess if the IPR&D project has alternative future use in research and development activities.
Read it in 10-K Feb 18, 2025 at sec.gov
RemovedMD&A
Finite-lived intangible assets are amortized over the estimated economic useful lives of the assets, which is the period during which expected cash flows support the fair value of such intangible assets. We review finite-lived intangible assets and other long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We also periodically review the useful lives assigned to our intangible assets to ensure that our initial estimates do not exceed any revised estimated periods from which we expect to realize cash flows from the underlying intangible asset. If a change were to occur in any of the above-mentioned factors or estimates, the likelihood of a material change in our reported results would increase.
Read it in 10-K Feb 18, 2025 at sec.gov
RemovedMD&A
We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When such an event occurs, management determines whether there has been impairment by comparing the anticipated undiscounted future net cash flows to the related asset group’s carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset.
Read it in 10-K Feb 18, 2025 at sec.gov
RemovedMD&A
Our impairment tests require the use of assumptions and estimates, such as industry economic factors and the profitability of future business strategies. To estimate undiscounted future cash flows of long-lived assets, we may apply a probability-weighted approach that incorporates different assumptions and potential outcomes related to the underlying long-lived assets. The evaluation is performed at the lowest level for which separately identifiable cash flows exist. To estimate the fair value of these assets, we generally use a discounted cash flow under the income approach, which requires significant judgment, including the timing and weighting placed on potential outcomes for the asset group.
Read it in 10-K Feb 18, 2025 at sec.gov
RewordedMD&A
The following table sets forth, for the periods indicated, our beginning balance of cash and cash equivalents, net cash flows provided by (used in) operating, investing and financing activities and our ending balance of cash and cash equivalents:Year Ended December 31, 2025 2024 2023 2022 (in thousands) Cash and cash equivalents at beginning of year $ 324,404 $ 167,486 $ 69,858 $ 59,379 Net cash provided by operating activities 238,663 168,481 97,333 Net cash (used in) provided by investing activities (404,590) 77,624 (16,076) Net cash provided by (used in) operating activities 168,481 97,333 (55,661) Net cash provided by (used in) investing activities 77,624 (16,076) 54,790 Net cash (used in) provided by financing activities 26,532 (87,006) 16,203 11,622 Effect of foreign exchange rate changes on cash and cash equivalents 1,888 (2,181) 168 Cash and cash equivalents at end of year 186,897 324,404 167,486 69,858
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
Gross This compares to gross margin was of 63.2% in 2024, including a $7.3 million reduction in revenue resulting from the Italian government’s payback provision, which requires medical device companies to make payments to the Italian government for any deficit created by Italian budget overspend on medical devices, and included a one-time $33.4 million inventory charge to cost of revenue in connection with the impairment of our Immersive Healthcare immersive healthcare asset group (refer to Note “4.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
Net cash provided by used in investing activities was $54.8 $404.6 million in 2022 2025 and primarily consisted of purchases of marketable investments, net of proceeds from maturities and sales of marketable investments investments, of $74.1 million, partially offset by $340.9 million and capital expenditures of $19.3 million. $63.7 million primarily driven by investments related to the construction of our Costa Rica manufacturing facility.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
The Company incurred a $33.4 million charge to cost of revenue for the write-down of Immersive Healthcare immersive healthcare inventory to net realizable value, an impairment charge to long-lived assets consisting of $58.9 million in finite-lived intangible assets and $18.0 million in property and equipment, and severance and other associated costs of $5.0 million included in research and development and sales, general and administrative within the consolidated statement of operations.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
Net cash provided by financing activities was $16.2 $26.5 million in 2023 2025 and primarily consisted of proceeds from the issuance of common stock under our employee stock purchase plan of $14.9 $16.4 million and proceeds from exercises of stock options of $5.5 $15.4 million, partially offset by payments of employee taxes related to vested restricted stock units of $2.5 million and payments towards finance leases obligations of $2.5 million.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
Net cash (used in) provided by (used in) investing activities primarily relates primarily to proceeds from maturities of marketable investments, partially offset by purchases of marketable and non-marketable investments, capital expenditures, and payments in connection with asset acquisitions. acquisitions, partially offset by sales of marketable investments and proceeds from maturities of marketable investments.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
This was partially offset by an increase in accrued expenses and other non-current liabilities of $6.2 $12.9 million primarily as a result of the growth in our business activities, and an increase in accounts payable of $1.1 million, and proceeds of $0.5 million received related to lease incentives from operating leases. $3.1 million.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
Our change in effective tax rate was primarily attributable to an increase in excess tax benefits from stock-based compensation and substantial tax benefits recorded from releasing the valuation allowance against federal research and development credits and partial California DTAs in 2023. compensation.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
Revenue from our global thrombectomy embolization and access products increased $138.1 $76.6 million, or 20.4%, 20.2%, to $815.5 $455.7 million in 2024, the year ended December 31, 2025, from $677.3 $379.1 million in 2023. the year ended December 31, 2024.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
Exit of Immersive Healthcare BusinessYear Ended December 31, Change 2025 2024 2023 $ % (in thousands, except for percentages) Cost of revenue $ $ 33,362 $ $ 33,362 100.0% (33,362) (100.0)% Impairment charge 76,945 — 76,945 100.0% (76,945) (100.0)% Severance and other associated costs 4,971 — 4,971 100.0% (4,971) (100.0)% Impact of Immersive Healthcare Business Exit $ $ 115,278 $ $ 115,278 100.0% (115,278) (100.0)% Exit impact as a percentage of revenue —% 9.6 % —%
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
The change in operating assets and liabilities includes an increase in inventories of $67.7 $26.5 million to support our revenue growth, an increase in accounts receivable of $19.5 million, and an increase in prepaid expenses and other current and non-current assets of $18.9 million, and an increase in accounts receivable of $0.3 $12.7 million.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
Net cash provided by operating activities was $97.3 $238.7 million in 2023 2025 and consisted of net income of $91.0 $177.7 million and non-cash items of $103.7 million offset by net changes in operating assets and liabilities of $79.1 million offset by non-cash items of $85.5 $42.7 million.
Read it in 10-K Feb 25, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PEN/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.